This site is intended for health professionals only

Cognitive impairment present 6 months after acute COVID-19 infection

Cognitive impairment has been found to persist for at least 6 months after experiencing an acute COVID-19 infection

Cognitive impairment has been found to be present 6 months after an acute COVID-19 infection among hospitalised patients when compared with a similar group of hospitalised patients without the virus. However, while patients also developed new-onset psychiatric diagnoses, this was no different to the incidence among control patients according to the results of a study by researchers from the Mental Health Center Copenhagen, Denmark.

Survivors of COVID-19 are at increased risk of psychiatric sequelae and in one Italian study that followed-up COVID-19 patients 8 weeks after discharged from hospital, the most frequent symptoms were fatigue (46%), dyspnea (30%), insomnia (26%), anosmia (20%), and dysgeusia and palpitation (15%). However, the development of cognitive impairment is not necessarily a unique feature of infection with COVID-19 and research shows that hospitalised patients in medical and surgical intensive care units are also known to be at a high risk for long-term cognitive impairment. Consequently, while there is much current interest in the cognitive sequelae of COVID-19, the incidence needs to be seen in relation to other hospitalised patients.

For the present study, the Danish team undertook a prospective study of all patients hospitalised with COVID-19 and matched them (for age, sex and intensive care unit status) with a group of non-COVID-19 patients. Cognitive impairment was assessed using the Montreal Cognitive Assessment (MoCA) which was dichotomised into normal or abnormal using pre-specified cut-off scores of 26 or lower and 24 or lower. The MoCA score ranges from 0 to 30 with a score of 26 or more considered to be normal. The team also examined the incidence of new-onset psychiatric diagnoses and together with the MoCA scores, both measures were set as the co-primary outcome and which were assessed at 6 months post-infection. In addition, secondary outcomes included the presence of a specific psychiatric diagnosis such as depression and self-reported symptoms as described in a supplement to the article (Table 1).

Cognitive impairment in both groups

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

A total of 85 individuals with a mean age of 56.8 years (42% women) hospitalised with COVID-19 were matched with 61 non-COVID-19 patients and included in the analysis. Among the COVID-19 cohort, 51% were admitted to an intensive care unit and the median follow-up time after COVID-19 was 165 days.

The total MoCA score at 6 months was 26.7 in the COVID-19 cohort and 27.5 in the control group (p = 0.01). When using the cut-off score of 24 or less, an abnormal test result was more frequent among those with COVID-19 (14% vs 2%, p = 0.03, COVID-19 vs controls). However, in a subset of COVID-19 patients who underwent cognitive assessment at hospital prior to discharge (rather than at 6 months) and were subsequently followed up, while the mean MoCA score at discharge was 19.2, this improved to 26.1 (P = 0.004) at follow-up.

Overall, 19% of COVID-19 survivors and 20% of controls developed a new-onset psychiatric diagnosis including panic anxiety, depression, at the 6-month follow-up assessment which was not statistically different (p = 0.87). Furthermore, when the data were adjusted for several factors including levels of intubation, disease severity and co-morbidities, the result remained unchanged.

The authors concluded that while cognitive impairment was more prevalent among COVID-19 survivors 6-months post-infection, the overall neuropsychiatric burden was similar to matched, hospitalised control patients.

Citation
Nersesjan V et al. Neuropsychiatric and Cognitive Outcomes in Patients 6 Months After COVID-19 Requiring Hospitalization Compared With Matched Control Patients Hospitalized for Non–COVID-19 Illness JAMA Psychiatry 2022






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x